SCHEMBL3814296

SCHEMBL3814296

N#Cc1cccc(C(c2cccc(Br)n2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.44
CHRNA5 P30532 2/20 0.44
CHRNA4 P43681 2/20 0.44
CYP19A1 P11511 2/20 0.44
KCNA5 P22460 6/20 0.41
KCNH2 Q12809 2/20 0.41
VNN1 O95497 1/20 0.39
KCNE1 P15382 1/20 0.39
KCNQ1 P51787 1/20 0.39
KCND3 Q9UK17 1/20 0.39
CYP11B2 P19099 4/20 0.39
CYP11B1 P15538 3/20 0.39
CYP17A1 P05093 1/20 0.39
MGLL Q99685 1/20 0.37
ABCG2 Q9UNQ0 1/20 0.36
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3894888 0.92 CHRNB2 (0.41) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL3899448 0.85 KCNA5 (0.47) CYP19A1KCNA5KCNE1KCNQ1KCND3
SCHEMBL1378651 0.85 KCNA5 (0.47) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL3889459 0.82 CYP19A1 (0.40) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL1380955 0.82 CYP19A1 (0.46) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL15014677 0.82 CYP19A1 (0.41) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL3899464 0.82 VNN1 (0.43) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL3810697 0.81 CYP19A1 (0.42) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL3818719 0.81 CYP19A1 (0.42) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5
SCHEMBL3887314 0.81 CYP19A1 (0.42) CHRNB2CHRNA5CHRNA4CYP19A1KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776355-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2013-06-12 EP disclosed
EP-1776355-A4 POTASSIUM CHANNEL INHIBITORS MERCK & CO INC (US) 2009-08-12 EP disclosed
US-7569589-B2 Potassium channel inhibitors MERCK & CO., INC. (US) 2009-08-04 US disclosed
EP-1776355-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2007-04-25 EP disclosed
WO-2006028590-A1 1,1,2,2-TETRA (HETERO) ARYLETHANES OR 1,1,2-TRI (HETERO) ARYL-2-HETEROCYCLYLETHANES AS POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2006-03-16 WO disclosed
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias MERCK SHARP & DOHME LLC 2006-02-09 US disclosed
WO-2006014877-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030595-A1 (R)-N-{6-[1-(4-fluorophenyl)-2,2-dipyridin-3-ylethyl]pyridin-2-yl}methanesulfonamide; cardiac arrhythmias KCNN2, KCNJ2, KCNH2 CHRNB2 799/4885CHRNA5 653/4885CHRNA4 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.